Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bayer Says Xarelto Proven Effective In Treating Patients With Pulmonary Embolism

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the oral anticoagulant Xarelto, or rivaroxaban, used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist, in treating patients with acute symptomatic pulmonary embolism and preventing them from developing a secondary venous blood clot.

Rivaroxaban showed similar overall bleeding rates, but was associated with significantly lower rates of major bleeding versus the current standard of care.

The company noted that Rivaroxaban was also proven effective in preventing recurrent venous blood clots in Phase III EINSTEIN-PE Study.

Click here to receive FREE breaking news email alerts for Bayer AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After trending higher over the past several sessions, stocks showed a lack of direction throughout the trading day on Friday before closing roughly flat. A muted reaction to a highly anticipated speech by Federal Reserve Chair Janet Yellen contributed to the lackluster performance. Republican Scott Brown has significantly narrowed the gap in the race against incumbent New Hampshire Sen. Jeanne Shaheen, D-N.H., according to the results of a new WMUR Granite State Poll. On the heels of the violent clashes between local police and protestors in Ferguson, Missouri, Sen. Claire McCaskill, D-Mo., announced that she will hold a Senate hearing in September to examine the militarization of local police departments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.